阿斯特捷利康
AZN77.690USD
+0.130+0.17%
收盤 09/17, 16:00（美東）報價延遲15分鐘
240.94B總市值
29.05本益比TTM
關於 阿斯特捷利康 公司
阿斯特捷利康是一家科研驅動的全球生物製藥企業，致力於將科學突破快速轉化為患者可及的治療選項，專注腫瘤、罕見疾病以及心血管、腎臟代謝、呼吸與免疫等領域的處方創新，並拓展疫苗與免疫療法。公司核心腫瘤藥物組合涵蓋 Tagrisso、Imfinzi、Lynparza、Calquence、Enhertu、Orpathys、Zoladex、Faslodex 等；罕見病線持續擁有 Soliris、Ultomiris、Strensiq、Kanuma；生物製藥線提供 Farxiga、Crestor、Breztri 等多款產品。當前研發管線中，候選疫苗 IVX-A12 用於應對呼吸道合胞病毒與人類偏肺病毒，腫瘤候選藥 FPI-2265 靶向轉移性去勢抵抗性前列腺癌，並正開展 II 期臨床研究。公司同時積極投入 T 細胞受體療法與治療肽 Eneboparatide 的開發工作。
公司簡介
公司代碼AZN
公司名稱AstraZeneca PLC
上市日期Sep 21, 2007
CEOMr. Marc Dunoyer
員工數量94300
證券類型Ordinary Share
年結日Sep 21
公司地址1 Francis Crick Avenue
城市CAMBRIDGE
上市交易所London Stock Exchange
國家United Kingdom
郵編CB2 0AA
電話442073045000
網址https://www.astrazeneca.com/
公司代碼AZN
上市日期Sep 21, 2007
CEOMr. Marc Dunoyer
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
Ms. Diana Layfield
Ms. Diana Layfield
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Rene Haas
Mr. Rene Haas
Non-Executive Director
Non-Executive Director
--
--
Mr. Michel Demare
Mr. Michel Demare
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Aradhana Sarin, M.D.
Ms. Aradhana Sarin, M.D.
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Susan Galbraith
Ms. Susan Galbraith
Executive Vice President - Oncology and Research and Development
Executive Vice President - Oncology and Research and Development
--
--
Mr. Marc Dunoyer
Mr. Marc Dunoyer
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca
--
--
Mr. David (Dave) Fredrickson
Mr. David (Dave) Fredrickson
Executive Vice President - Oncology Business Unit
Executive Vice President - Oncology Business Unit
--
--
Mr. Pascal Soriot
Mr. Pascal Soriot
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Philip Broadley
Mr. Philip Broadley
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
--
--
Dr. Ruud Dobber, Ph.D.
Dr. Ruud Dobber, Ph.D.
Executive Vice President - BioPharmaceuticals Business Unit
Executive Vice President - BioPharmaceuticals Business Unit
--
--
收入明細
單位: USD更新時間: 7月6日 週日
單位: USD更新時間: 7月6日 週日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Farxiga
2.06B
15.98%
Tagrisso
1.68B
13.04%
Imfinzi
1.26B
9.79%
Ultomiris
1.05B
8.16%
Calquenc
762.00M
5.92%
其他
6.07B
47.11%
地區USD
名稱
營收
佔比
United States
5.65B
43.85%
Europe
2.76B
21.43%
EX-China
2.14B
16.61%
China
1.80B
14.02%
Established ROW
1.24B
9.62%
業務
地區
業務USD
名稱
營收
佔比
Farxiga
2.06B
15.98%
Tagrisso
1.68B
13.04%
Imfinzi
1.26B
9.79%
Ultomiris
1.05B
8.16%
Calquenc
762.00M
5.92%
其他
6.07B
47.11%
股東統計
更新時間: 8月15日 週五
更新時間: 8月15日 週五
持股股東
股東類型
持股股東
持股股東
佔比
PRIMECAP Management Company
1.33%
Wellington Management Company, LLP
1.11%
Capital International Investors
1.01%
T. Rowe Price International Ltd
0.99%
T. Rowe Price Associates, Inc.
0.68%
其他
94.88%
持股股東
持股股東
佔比
PRIMECAP Management Company
1.33%
Wellington Management Company, LLP
1.11%
Capital International Investors
1.01%
T. Rowe Price International Ltd
0.99%
T. Rowe Price Associates, Inc.
0.68%
其他
94.88%
股東類型
持股股東
佔比
Investment Advisor
8.93%
Investment Advisor/Hedge Fund
6.15%
Research Firm
0.79%
Hedge Fund
0.60%
Bank and Trust
0.15%
Pension Fund
0.07%
Family Office
0.02%
Family Office
0.02%
Family Office
0.02%
其他
83.25%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
2025
530.44M
17.10%
-21.90M
2025Q1
2050
532.32M
17.16%
-23.25M
2024Q4
1985
546.17M
17.61%
+11.21M
2024Q3
1920
519.95M
16.76%
-17.37M
2024Q2
1910
530.80M
17.12%
-10.51M
2024Q1
1865
523.00M
16.86%
-21.20M
2023Q4
1838
520.78M
16.79%
-27.28M
2023Q3
1815
530.17M
17.10%
-14.80M
2023Q2
1812
525.36M
16.94%
-28.74M
2023Q1
1803
534.31M
17.23%
-35.06M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
PRIMECAP Management Company
40.66M
1.31%
-358.04K
-0.87%
Mar 31, 2025
Wellington Management Company, LLP
35.63M
1.15%
-1.41M
-3.80%
Mar 31, 2025
Capital International Investors
31.29M
1.01%
-6.22M
-16.59%
Mar 31, 2025
T. Rowe Price International Ltd
27.28M
0.88%
+669.64K
+2.52%
Mar 31, 2025
T. Rowe Price Associates, Inc.
29.81M
0.96%
-3.93M
-11.66%
Mar 31, 2025
Managed Account Advisors LLC
22.52M
0.73%
+6.08M
+37.01%
Mar 31, 2025
Fisher Investments
20.17M
0.65%
+9.21M
+83.99%
Mar 31, 2025
Fidelity Management & Research Company LLC
18.99M
0.61%
+841.77K
+4.64%
Mar 31, 2025
Sanders Capital, LLC
15.07M
0.49%
-117.71K
-0.78%
Mar 31, 2025
Putnam Investment Management, L.L.C.
12.30M
0.4%
+500.77K
+4.24%
Mar 31, 2025
查看更多
持股ETF
更新時間: 9月1日 週一
更新時間: 9月1日 週一
機構名稱
佔比
Amplify Weight Loss Drug & Treatment ETF
5.27%
Invesco QQQ Low Volatility ETF
4.96%
ProShares Ultra Nasdaq Biotechnology
4.75%
First Trust WCM International Equity ETF
4.72%
Parnassus Value Select ETF
4.44%
Invesco Nasdaq Biotechnology ETF
4.23%
Roundhill GLP-1 & Weight Loss ETF
3.61%
VanEck Pharmaceutical ETF
3.56%
Franklin Genomic Advancements ETF
3.42%
Global X Aging Population ETF
3.1%
查看更多
Amplify Weight Loss Drug & Treatment ETF
佔比5.27%
Invesco QQQ Low Volatility ETF
佔比4.96%
ProShares Ultra Nasdaq Biotechnology
佔比4.75%
First Trust WCM International Equity ETF
佔比4.72%
Parnassus Value Select ETF
佔比4.44%
Invesco Nasdaq Biotechnology ETF
佔比4.23%
Roundhill GLP-1 & Weight Loss ETF
佔比3.61%
VanEck Pharmaceutical ETF
佔比3.56%
Franklin Genomic Advancements ETF
佔比3.42%
Global X Aging Population ETF
佔比3.1%
分紅派息
近5年累計派現
20.90B
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Feb 06, 2025
AZN.NB Interim Cash Dividend of gross USD 1.05 paid on Mar 24, 2025 going ex on Feb 21, 2025
Feb 21, 2025
Mar 24, 2025
Feb 21, 2025
Jul 25, 2024
AZN.NB Final Cash Dividend of gross USD 0.5 paid on Sep 09, 2024 going ex on Aug 09, 2024
Aug 09, 2024
Sep 09, 2024
Aug 09, 2024
Feb 08, 2024
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 25, 2024 going ex on Feb 22, 2024
Feb 23, 2024
Mar 25, 2024
Feb 22, 2024
Jul 28, 2023
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 11, 2023 going ex on Aug 10, 2023
Aug 11, 2023
Sep 11, 2023
Aug 10, 2023
Feb 10, 2023
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 27, 2023 going ex on Feb 23, 2023
Feb 24, 2023
Mar 27, 2023
Feb 23, 2023
Aug 01, 2022
AZN.NB Final Cash Dividend of gross USD 0.465 paid on Sep 12, 2022 going ex on Aug 11, 2022
Aug 12, 2022
Sep 12, 2022
Aug 11, 2022
Feb 10, 2022
AZN.NB Interim Cash Dividend of gross USD 0.985 paid on Mar 28, 2022 going ex on Feb 24, 2022
Feb 25, 2022
Mar 28, 2022
Feb 24, 2022
Aug 02, 2021
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 13, 2021 going ex on Aug 12, 2021
Aug 13, 2021
Sep 13, 2021
Aug 12, 2021
Feb 11, 2021
AZN.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2021 going ex on Feb 25, 2021
Feb 26, 2021
Mar 29, 2021
Feb 25, 2021
Jul 30, 2020
AZN.NB Final Cash Dividend of gross USD 0.45 paid on Sep 14, 2020 going ex on Aug 13, 2020
Aug 14, 2020
Sep 14, 2020
Aug 13, 2020
查看更多
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
